Mohit Narang is an Oncology physician affiliated with Maryland Oncology Hematology. OpenAlex indexes 111 publications with 857 citations (h-index 18).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
23 Crossroads Drive
Suite 340
Owing Mills, MD 21117
Telephone
410-581-2100Registry record last updated 5 Oct 2011.
Industry payments
80 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- BeOne Medicines USA, Inc.Program year202547 payments$79,284openpaymentsdata.cms.gov ↗
- E.R. Squibb & Sons, L.L.C.Program year202540 payments$50,054openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year202565 payments$48,838openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
47.4%PD-1 inhibitor21%Pembrolizumab70%Nivolumab31%Part B, office-administered≥23 patientsCD38-directed Cytolytic Antibody10.6%Daratumumab100%Part B, office-administered≥21 patients+ 14 more classes in this area
Blood & clotting
34.7%Erythropoiesis-stimulating Agent28.6%Darbepoetin alfa100%Part B, office-administered≥64 patientsIron, parenteral preparations6%Ferric derisomaltose100%Part B, office-administered≥100 patients+ 1 more class in this area
Metabolism & gastrointestinal
7.5%Substance P/Neurokinin-1 Receptor Antagonist5.3%Aprepitant100%Part B, office-administered≥29 patientsSerotonin-3 Receptor Antagonist1.5%Granisetron hydrochloride54%Palonosetron hcl45%Ondansetron Hcl1%Part D + Part B≥46 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”